{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-044996","form_type":"8-K","ticker":"NORD","cik":"0001011060","company_name":"Nordicus Partners Corp","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.353463+00:00","generated_at":"2026-05-30T00:45:06.688358+00:00","sec_items":["1.01","2.01","3.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nordicus Partners acquires 100% of Bio-Convert ApS for 12M restricted shares","bullets":["Acquired 100% of Danish clinical-stage biopharma Bio-Convert ApS on Nov 12, 2024.","Consideration: 12 million restricted common shares (OTCQB: NORD) issued to sellers.","Bio-Convert is developing a drug for oral leukoplakia, a potentially malignant disorder.","Nordicus previously acquired 95% of Orocidin A/S in May 2024, adding periodontitis therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-044996","json":"https://secwatch.observer/filing/0001493152-24-044996.json","markdown":"https://secwatch.observer/filing/0001493152-24-044996.md","text":"https://secwatch.observer/filing/0001493152-24-044996.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1011060/000149315224044996/0001493152-24-044996-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1011060/000149315224044996/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:45:06.688358+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}